Many ovarian cancer patients (OCPs) have reduced FANCD2 expression [63], whereas overexpression of the protein is associated with a poor prognosis, especially in patients undergoing taxane-platinum therapies [42]. This evidence concerns the gene FANCD2 and ovarian carcinoma.